-
Article
Voriconazole greatly increases the exposure to oral buprenorphine
Buprenorphine has low oral bioavailability. Regardless of sublingual administration, a notable part of buprenorphine is exposed to extensive first-pass metabolism by the cytochrome P450 (CYP) 3A4. As drug inte...
-
Article
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction
This study aimed to determine possible effects of voriconazole and posaconazole on the pharmacokinetics and pharmacological effects of sublingual buprenorphine.
-
Article
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Ketamine is a phencyclidine derivative, which functions primarily as an antagonist of the N-methyl-d-aspartate receptor. It has no affinity for gamma-aminobutyric acid receptors in the central nervous system. Ket...
-
Article
Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol
Tramadol is widely used for acute, chronic, and neuropathic pain. Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the μ-opioid receptor-related analgesic effect. Tram...
-
Article
Rifampicin markedly decreases the exposure to oral and intravenous tramadol
Tramadol is mainly metabolized by the cytochrome P450 (CYP) 2D6, CYP2B6 and CYP3A4 enzymes. The aim of this study was to evaluate the effect of enzyme induction with rifampicin on the pharmacokinetics and phar...
-
Article
Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction
We assessed possible drug interactions of tramadol given concomitantly with the potent CYP2B6 inhibitor ticlopidine, alone or together with the potent CYP3A4 and P-glycoprotein inhibitor itraconazole.
-
Article
S-ketamine concentrations are greatly increased by grapefruit juice
We examined the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of oral S-ketamine.
-
Article
Interaction of oxycodone and voriconazole—a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects
-
Article
Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone
Oxycodone is a μ-opioid receptor agonist that is mainly metabolized by hepatic cytochrome P450 (CYP) enzymes. Because CYP enzymes can be inhibited by other drugs, the pharmacokinetics of oxycodone are prone to...
-
Article
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
This study aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the trea...
-
Article
Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone
The aim of this study was to investigate the effects of the cytochrome P450 3A4 (CYP34A) inhibitor itraconazole on the pharmacokinetics and pharmacodynamics of orally and intravenously administered oxycodone.
-
Article
Voriconazole drastically increases exposure to oral oxycodone
We investigated the effect of voriconazole on the pharmacokinetics and pharmacodynamics of oxycodone.
